Lilly and Novo bet on amylin for next obesity drugs

· Health · United States · Denmark

Eli Lilly and Novo Nordisk are developing new amylin drugs as another biological lever to pull in treating obesity and diabetes, after GLP-1 treatments. The approach could power a new wave of obesity medicines.

Why it matters：The race to build on GLP-1 success could expand the obesity drug market and alter treatment options for hundreds of millions of patients.

Key points

  • Amylin drugs act as another biological lever for obesity and diabetes
  • The bet follows the success of GLP-1 treatments
  • Both Lilly and Novo Nordisk are developing amylin candidates

Sources (original reporting)

More stories from this day